Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ViiV Healthcare's Pipeline Sharing With Generic Makers "Meaningless" In Absence Of Technology - Cipla, IPA

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Cipla - India's biggest generic drug maker and among the largest manufacturers of generic anti-retroviral drugs in the world - expressed measured optimism to ViiV Healthcare's decision on offering access to the portfolio of its present and future pipeline of anti-retroviral medicines to 69 least developed and low-income countries without any royalty charges. Even so, a Cipla spokesman said he doubted if the steps announced on improving access to the medicines can be implemented

Related Content

UsernamePublicRestriction

Register

SC075382

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel